Mayne Pharma Group Management
Management criteria checks 3/4
Mayne Pharma Group's CEO is Shawn O’Brien, appointed in Oct 2022, has a tenure of 3.25 years. total yearly compensation is A$2.13M, comprised of 45.7% salary and 54.3% bonuses, including company stock and options. directly owns 0.32% of the company’s shares, worth $489.04K. The average tenure of the management team and the board of directors is 3.7 years and 3.8 years respectively.
Key information
Shawn O’Brien
Chief executive officer
AU$2.1m
Total compensation
| CEO salary percentage | 45.68% |
| CEO tenure | 3.3yrs |
| CEO ownership | 0.3% |
| Management average tenure | 3.7yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | AU$2m | AU$973k | -AU$90m |
| Mar 31 2025 | n/a | n/a | -AU$104m |
| Dec 31 2024 | n/a | n/a | -AU$118m |
| Sep 30 2024 | n/a | n/a | -AU$143m |
| Jun 30 2024 | AU$2m | AU$959k | -AU$169m |
| Dec 31 2023 | n/a | n/a | -AU$274m |
| Sep 30 2023 | n/a | n/a | -AU$296m |
| Jun 30 2023 | AU$2m | AU$663k | -AU$317m |
Compensation vs Market: Shawn's total compensation ($USD1.42M) is about average for companies of similar size in the US market ($USD1.44M).
Compensation vs Earnings: Shawn's compensation has increased whilst the company is unprofitable.
CEO
Shawn O’Brien (66 yo)
Mr. Shawn Patrick O'Brien, B.Sc., M.S., M.B.A., has been CEO, MD & Director at Mayne Pharma Group Limited since October 1, 2022. He serves as the Chief Commercial Advisor at Melanovus Oncology, Inc. Mr. O'...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 3.3yrs | AU$2.13m | 0.32% $ 489.0k | |
| Chief Financial Officer | 3.4yrs | AU$1.22m | 0.10% $ 155.1k | |
| Executive VP & General Counsel | 4yrs | no data | no data | |
| Executive Vice President of Corporate Development | 5yrs | AU$1.29m | no data | |
| Interim Global Head of People | less than a year | no data | no data | |
| Executive Vice President of Specialty Products & Patient Solutions | 6.3yrs | no data | no data | |
| Executive VP | 3yrs | no data | no data | |
| Executive Vice President of Women's Health | no data | no data | no data | |
| Financial Controller | no data | no data | no data | |
| Associate General Counsel & Company Secretary | 5.8yrs | no data | no data |
Experienced Management: MAYN.F's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 3.3yrs | AU$2.13m | 0.32% $ 489.0k | |
| Non-Executive Chairman | 11.4yrs | AU$209.81k | 0.020% $ 31.6k | |
| Independent Non-Executive Director | 7.6yrs | AU$205.02k | 0.027% $ 42.0k | |
| Independent Non-Executive Director | 3.8yrs | AU$221.71k | 0.026% $ 40.6k | |
| Independent Non-Executive Director | 3.9yrs | AU$205.95k | 0.047% $ 72.1k | |
| Independent Non Executive Director | 2.2yrs | AU$207.58k | no data | |
| Non-Executive Director | 3.3yrs | AU$208.27k | no data |
Experienced Board: MAYN.F's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/19 14:11 |
| End of Day Share Price | 2026/01/09 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mayne Pharma Group Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Dunlop | BofA Global Research |
| Elyse Shapiro | Canaccord Genuity |
| John Deakin-Bell | Citigroup Inc |